News Headlines
-
Astellas Breaks Ground On New €330M State-Of-The-Art Facility In Tralee, Co. Kerry, Ireland
3/27/2024
Today, Astellas Ireland Co., Ltd, a wholly owned subsidiary of Astellas Pharma Inc., held a ceremony to mark the breaking of the ground and start of construction for its new €330M, state-of-the-art facility at Kerry Technology Park, Tralee, Co. Kerry.
-
Aragen Operationalizes First Phase Of Its Biologics Manufacturing Facility In India
3/27/2024
Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, announced that it has operationalized the first phase of its biologics manufacturing facility in Bangalore, India through its 100% subsidiary, Aragen Biologics Pvt Ltd.
-
ProBioGen And DIOSynVax Partner To Manufacture Groundbreaking Multivalent Vaccine For Hemorrhagic Fever
3/27/2024
ProBioGen, a globally recognized and experienced Contract Development & Manufacturing Organization (CDMO), proudly announces a partnership with DIOSynVax Ltd to manufacture DIOS-HFVac3, a trivalent hemorrhagic fever (HF) vaccine that was developed in collaboration with Prof. Wagners team (Molecular Virology, Institute of Medical Microbiology and Hygiene, University of Regensburg).
-
Abzena Announces Major Investment In Bioconjugation And ADC Capabilities In Response To Increasing Industry Demand
3/27/2024
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site.
-
Lonza Expands Service Offering For Spray-Dried Biologics For Pulmonary Delivery
3/27/2024
Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced an expansion of its service offering for spray-drying of proteins for pulmonary delivery.
-
Exothera Pledges To Fast-Track RNA Therapies With Expansion Of World-First Continuous-Batch RNA Manufacturing Solution Into North America
3/26/2024
Belgium-headquartered Exothera, a leading provider of nucleic acids and viral vector development and manufacturing services, has launched its game-changing nucleic acids service offering, powered by the world’s first continuous-batch RNA production platform, Ntensify.
-
Veeda Clinical Research Acquires European CRO - Heads - Expanding Global Reach & Capabilities
3/26/2024
Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.
-
Ajinomoto Co., Inc. Enhances StemFit iPS Cell Expansion Medium
3/26/2024
Today, Ajinomoto Co., Inc. ("Ajinomoto Co.") (TSE: 2802) launched a new version of its StemFit™ iPSC expansion medium. The enhanced version of its widely used StemFit™ products is designed to improve the growth and pluripotency of induced pluripotent stem cells (iPSC) and meet the Good Manufacturing Practice (GMP) standards for Active Pharmaceutical Ingredients (API).
-
Biocytogen Enters Collaboration With ABL Bio To Develop New Bispecific Antibody-Drug Conjugates
3/25/2024
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
-
AbbVie To Acquire Landos Biopharma, Further Strengthening Its Portfolio In Inflammatory And Autoimmune Diseases
3/25/2024
AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.